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to IA management with voriconazol (VCZ) versus amphotericin B (ANB), and 
liposomal amphotericin B (LAB) from private and public payer’s perspectives in 
Brazil. Methods: IA treatment was simulated in a decision-tree model with VCZ 
(6mg/kg twice, followed by 4mg/kg bid, 10 days), ANB (1.5mg/kg/day, 13 days), and 
LAB (3mg/kg/day, 13 days) and their associated costs in a 12-week time horizon. After 
first evaluation, responders continued with maintenance treatment and those with 
failure switched to a second treatment (caspofungin was also considered as rescue 
therapy). Efficacy data (clinical response), adverse events, and mortality rate were 
generated by meta-analysis based on systematic literature review. Costs included 
drugs, medical follow-up and adverse events management, collected from Brazilian 
private and public official databases (values represented 2013 BRL). Results: 
Clinical response and mortality rate in 12 weeks were [56.67%; 34.1%], [36.42%; 
50.9%], and [34.56%; 48.7%] for VCZ, ANB, and LAB, respectively. Total treatment costs 
with VCZ, ANB, and LAB were 40,635.71BRL, 18,570.14BRL and 86,646.42BRL from 
private, and 25,152.81BRL, 3,751.90BRL, and 62,107.87BRL from the public perspec-
tive, respectively. VCZ presented the highest response rate and lower mortality rate 
at 12 weeks. ANB was the least costly followed by VCZ. VCZ presented an economy 
of 46,010.71BRL and 36,955.07BRL when compared to LAB, from private and public 
perspectives, respectively. Main cost driver was related to drug acquisition (VCZ and 
LAB groups), and daily in ICU (ANB group). ConClusions: In this analysis, VCZ in 
IA treatment presented the greatest clinical response and the lower mortality rate 
when compared to ANB and LAB. Total treatment cost was higher than ANB but 
lower when compared to LAB in Brazilian private and public health care systems.
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objeCtives: Neglected diseases (ND) are a group of illness caused by infectious 
and parasitic agents endemic in low-income populations. ND control is essential for 
achieving country development and inequalities reduction. The Brazilian Program 
for Research and Development in Neglected Diseases (BPRDND) was created by the 
Brazilian Ministry of Health. Seven priorities were established: dengue, Chagas dis-
ease, leishmaniasis, hanseniasis, malaria, schistosomiasis and tuberculosis. This 
study aims to evaluate hospitalization patterns and costs related to those diseases 
after BPRDND implementation. Methods: Analysis of reported ND related hos-
pital admissions was developed according to ICD-10 classification as described in 
Brazilian Hospital Information System (SIH/SUS) database, from January 2009 to 
December 2011. Only seven priority diseases were included. Costs represent federal 
reimbursement values for hospitalizations (medical procedures, exams, drugs and 
fees) estimated in 2014 Brazilian Real (BRL). Results: From 2009 to 2011, 306,682 
hospitalizations due to all selected ND were observed and dengue represented 70.22% 
of all. Dengue treatment was responsible for 69.58% of ND related procedures. Total 
cost was 162,458,715BRL in the period with 46.22% and 41.78% due to tuberculosis 
and dengue, respectively. Over the years, cost distribution was: 16,039,294BRL in 2009, 
27,970,785BRL in 2010, and 23,869,733BRL in 2011 for dengue, and 21,791,027BRL in 
2009, 23,889,130BRL in 2010 and 29,410,353BRL in 2011 for tuberculosis. Compared 
to 2009, 2011 showed an increase of 39% and 37% in hospitalizations and associated 
costs, respectively. In-hospital deaths presented an increase of 9.7%, except for Chagas 
disease and schistosomiasis, with reduction of 45% and 56%, respectively. Geographic 
distribution indicated northeast region accounting for 39.47% of hospital admissions, 
and 35.72% of costs, followed by southeast (23.02% and 29.79%, respectively) and north 
region (20.02% and 13%, respectively). ConClusions: Despite the implementation of 
PRDND in Brazil, this class of diseases still presents high frequency of hospitalization 
and costs, specially dengue and tuberculosis.
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objeCtives: To evaluate the economic impact of herpes zoster (HZ) on the US 
health care system among immunocompetent persons. Methods: Administrative 
claims from the Truven Health MarketScan® Research Databases (2008-2011) were 
assessed to determine the incremental medical resource utilization (RU) and cost 
associated with herpes zoster. Cases were selected based on an ICD-9-CM diagno-
sis code for HZ (ICD-9-CM 053.xx), continuous enrollment 12 months pre/post the 
earliest diagnosis (‘index’), and having no HZ diagnosis or evidence of receiving 
the Zostavax® vaccine in the 12 months pre-index. Cases were direct matched 1:1 
using demographic and clinical variables to immunocompetent controls without 
HZ. Analysis of potentially HZ-related RU and costs was limited to claims 21 days 
prior to through the first year following HZ diagnosis. Cases with postherpetic neu-
ralgia (PHN) were examined separately. Results: Data were from 98,916 cases and 
controls: 56.6% female, mean age 50.45 (standard deviation (SD) 18.83) years. The 
majority of PHN cases (n= 2,405) were female (64.2%), mean age 61.74 (SD= 16.73) 
years. HZ cases had significantly more RU in all categories (inpatient admissions, 
emergency room visits, office visits and number of other outpatient services) com-
pared to controls (p < 0.001) and those differences increased substantially in the 
presence of PHN. The total mean incremental health care costs for HZ cases were 
$1,308 which more than quadruple when PHN is present ($5,463), (both p< 0.001). 
For all cases, the primary cost drivers were outpatient prescriptions and other out-
patient services (e.g., laboratory, radiology), but for patients with the added burden 
of PHN, inpatient services also played a significant role. ConClusions: Herpes 
zoster is a significant economic and resource burden on the US health care system 
among the immunocompetent which grows exponentially when complicated by 
PHN. Further emphasis on vaccination against HZ should be considered to help 
alleviate this medical burden.
that of patients infected with carbapenem-sensitive bacteria. Methods: A cross 
sectional study was carried out for 3 months and the data for hospitalization cost 
was collected for the patients with carbapenem resistant and carbapenem sensi-
tive infections from the medicine ICU and the microbiology department for 114 
patients with bacterial infections who were admitted to Intensive care unit. The 
data was analyzed for the type of infection and the average hospitalization cost. The 
median hospitalization cost was calculated for both the group of patients. Results: 
Out of 247 patients admitted in the ICU during a three month period 70(28.34%) 
were found to be having carbapenem-resistant infections and 44(17.81%) were 
found to have carbapenem-sensitive infections. The median length of stay in the 
hospital was 9 days for carbapenem-sensitive patients while 23.5 days in case of 
carbapenem-resistant patients. The median hospitalization cost was found to be 
40185 INR in case of carbapenem sensitive patients while it was 126889.5 INR in 
case of carbapenem-resistant patients. ConClusions: Carbapenem-resistance is 
observed to be increasing the morbidity and cost burden on the patients substan-
tially. Increased length of hospital stay leads to an increase in the incidence of 
Nosocomial infections which further leads to the increased morbidity, mortality 
and cost burden on the society.
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objeCtives: Studies has shown that receiving 23-valent pneumococcal polysac-
charide vaccines (PPV23) would reduce the risk of pneumonia-related diseases 
and death for the elderly but the economic benefit of receiving PPV23 is unknown. 
This study aims to evaluate the economic benefit of PPV23 for the elderly aged 75 
years and above in Taiwan. Methods: The outcome data was drawn form Taiwan’s 
National Health Insurance Research Database and immunization information was 
derived from the National Immunization Information System (NIIS). PPV23 were 
provided to a total of 318,257 citizens who were free of PPV23 during 2007-2008 and 
the vaccination coverage rate was about 24.5% for the elderly population. Their 
1-year total medical cost (outpatient and inpatient) and 1-year pneumonia-related 
cost were recorded after they were vaccinated. A propensity score matching is used 
to avoid the selection bias due to the systematic difference between the vaccinated 
group and non-vaccinated group, and then GEE regression models were used to 
estimate the difference of the costs between two groups. Results: After controlling 
the demographic characteristics, medical history and medical utilization, 1-year 
total medical cost and 1-year pneumonia-related cost for the vaccinated group 
compared with the non-vaccinated group had significant reductions of 94.45 USD 
(p-value < 0.0001) and 86.77 USD (p-value < 0.0001), respectively. On average, the 
cost-saving of the vaccination for the elderly was 2.75 million USD. ConClusions: 
PPV vaccination can provide not only clinical benefit but also economic benefit and 
we believed that the economic benefit was underestimated because the herd effect 
was not taken into account.
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objeCtives: Nosocomial pneumonia (NP) is the second most common cause of 
in-hospital infection and the leading cause of death from infections acquired in 
hospitals commonly caused by methicillin resistant Staphylococcus aureus (MRSA). 
This study aims to evaluate clinical and economic outcomes related to NP treat-
ment with linezolid versus teicoplanin and vancomycin from a private and pub-
lic payer’s perspectives in Brazil. Methods: A decision-tree model simulates NP 
treatment with linezolid (600mg bid, 19 days), teicoplanin (400mg bid, 22 days), and 
vancomycin (15mg/kg bid, 24 days) and their associated costs in a time horizon of 
complete hospital care. After a first evaluation patients with response continued 
with maintenance treatment and those with failure switched to a second treat-
ment. Efficacy data (clinical response) was generated by meta-analysis based on 
systematic literature review. Costs included drugs, medical follow-up and adverse 
events management, collected from Brazil official databases (values represented 
2013 BRL). Results: Clinical response, days on ward, and intensive care unit (ICU) 
days were [72.6%; 7; 12], [68.3%; 8; 14], and [66.5%; 8; 16] for linezolid, teicoplanin, 
and vancomycin, respectively. Total treatment costs with linezolid, teicoplanin, and 
vancomycin were 49,426.43BRL, 79,710.87BRL and 81,352.99BRL from the private 
perspective and 15,213.60BRL, 13,884.51BRL, and 24,348.44BRL from the public per-
spective, respectively. Linezolid represented the least costly in private perspective 
(economy of 30,284BRL and 31,927BRL when compared to teicoplanin and vanco-
mycin). The main cost driver for all treatments was related to daily in ICU followed 
by adverse events management (teicoplanin and vancomycin) and drug acquisition 
(linezolid). ConClusions: In this analysis, linezolid in NP management presented 
the greatest clinical response, shorter hospital stay in ward and ICU, and lower price 
when compared to teicoplanin and vancomycin in Brazilian private health care 
system and lower price when compared to teicoplanin in public set.
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clINIcal aNd ecoNomIc outcomes related to INvasIve asPergIllosIs 
treatmeNt wIth vorIcoNazol From the PuBlIc aNd PrIvate 
PersPectIves IN BrazIl
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1ANOVA, Rio de Janeiro, Brazil, 2Pfizer, Inc., São Paulo, Brazil
objeCtives: Invasive aspergillosis (IA) is a severe infection that usually affects 
immunosuppressed patients in intensive care units (ICU), with high morbidity 
and mortality rates. This study assesses clinical and economic outcomes related 
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HCV treatment is associated with significant health care resource utilization. A high 
proportion of patients experienced AE for which management was associated with 
substantial additional costs, especially the anemia treatment. Thus, the cost of AE 
should be considered in future treatment options.
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objeCtives: Estimate the direct cost of hepatitis C in Mexico, from the perspective 
of the health care system for the government employees, and simulate the economic 
impact of new antivirals. Methods: We reviewed one hundred clinical records of 
patients diagnosed with chronic hepatitis C, to know the pattern of resources use at 
two hospitals of the health care system for the government employees, taking into 
account the disease stages based on the Child-Pugh. The inclusion criterion was 
patients with chronic HVC unresponsive to treatment or without the double viral 
therapy. Unit prices and costs of medical inputs were obtained from official sources. 
Demographic and clinical variables were also recorded in order to do compari-
sons. Statistical analysis of data was made with the SPSS. Simulation of economic 
impact of treatment with antivirals was done based on natural history of disease 
over a ten years horizon. Results: Annual mean costs of disease progression and 
complications were higher for Child-Pugh C (US$8,739) than B (US$6,319) and A 
(US$2,430). The estimated cost of one patient in Child-Pugh A stage not responding 
to peginterferon and ribavirin resulted in US$62,506 taking into account that this 
patient progress until Child-Pugh C. If the not responding patient could be treated 
with peginterferon, ribavirin and boceprevir the cost would be US$43,633, while a 
naive patient would cost US$34,302. ConClusions: Hepatitis C imposes a high 
economic burden to the health care system for the government employees. The 
access of this population of patients to new antivirals would result in savings for 
the institution as well as increasing health benefits for patients.
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objeCtives: To assess the potential trade-offs between aggressive screening (“test-
ing”) of the human immunodeficiency virus (HIV), early initiation of treatment 
(“test-and-treat”) with antiretroviral therapy (ART), and pre-exposure prophy-
laxis (PrEP) among men who have sex with men (MSM) in Los Angeles County 
(LAC). Methods: A compartmental mathematical model is developed to simulate 
HIV incidence among 15-65 year old MSMs of LAC over a twenty-year period, and 
estimate the cost and effectiveness of various HIV interventions using a societal 
perspective and a lifetime horizon. Annual LAC MSM population data (2000-2010) 
are estimated from the LAC HIV Surveillance Reports and the RAND California 
Population and Demographics database. The model input parameter values are 
derived from the published clinical literature and the Federal Supply and IMS Fee 
Schedules. For each intervention, we estimate the number of new HIV infections 
averted, the discounted costs and quality-adjusted life years (QALYs), and the incre-
mental cost per infection averted and cost-effectiveness ratios. Bootstrapping and 
probabilistic sensitivity analyses are conducted to assess the robustness of the 
estimates. Results: Our preliminary results show that relative to the status quo 
policy, and at the current US willingness to pay threshold of $100,000/QALY saved, 
both the PrEP, “testing” and “test-and-treat” strategies are cost-effective ($86,194; 
$44,746 and $94,520 per QALY saved, respectively). These results are imputable to 
the preventive and survival benefits of PrEP, knowledge of infection status, and early 
treatment. The relative effectiveness of PrEP is sensitive to PrEP and ART adherence 
and coverage rates. All cost-effectiveness profiles improve with ART price reductions 
following patent expiration. ConClusions: PrEP, “testing” and “test-and-treat” 
offer cost-effective alternatives to the status-quo policy. The success of the PrEP 
and “test-and-treat” strategies remains particularly contingent on the uptake rate 
and adherence to treatment. The lack of evidence on adherence behaviors towards 
PrEP thus warrants further studies that mimic real-world adherence patterns.
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matrIx oN wouNd closure IN PatIeNts wIth dIFFIcult-to-heal wouNd 
oF mIxed arterIal/veNous aNd veNous etIology
Gilligan A.M., Waycaster C.
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objeCtives: Determine the cost-effectiveness of small intestinal submucosa extra-
cellular matrix (SISEM) relative to standard of care (SC) on wound closure for the 
treatment of mixed arterial/venous (A/V) or venous (VLUs) leg ulcers. Methods: 
A 2-stage Markov model was used to predict the expected costs and outcomes of 
wound closure for SISEM and SC. Outcome data used in the analysis were taken 
from an 8-week randomized clinical trial that directly compared SISEM and SC. 
Patients were followed for 6 months to assess wound closure. Forty-eight patients 
completed the study; 25 for SISEM and 23 for SC. SC was defined as a standard moist 
wound dressing. Transition probabilities for the Markov states were estimated from 
the clinical trial. The economic outcome of interest was direct cost per ulcer-free 
week. Resource utilization was based on the treatment regimen used in the clini-
cal trial. Costs were derived from standard cost references. The payer’s perspective 
was taken. Results: SISEM-treated wounds healed, on average, after 5.4 weeks of 
treatment, compared to 8.3 weeks for SC wounds (p= 0.02). Furthermore, complete 
wound closure was significantly higher for patients treated with SISEM (p< 0.05), 
with 20 wounds closed in the SISEM group (80%) and 15 wounds closed in the SC 
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objeCtives: Pertussis incidence has resurged in the US after a nadir in the 1970s 
and is now one of the most prevalent vaccine-preventable infections. Infants are 
at greatest risk for severe pertussis-related morbidity and mortality (~50% of infant 
cases require hospitalization) and account for the majority of cases. We sought to 
quantify the cost and mortality burden of infant pertussis cases severe enough 
to prompt hospitalization. Methods: Data on pertussis-related hospitalizations 
(ICD-9-CM discharge codes 033.0, 033.8, 033.9, 484.3) from the 2000-2010 Nationwide 
Inpatient Sample (NIS) were retrospectively analyzed. Charges were converted to 
costs using a 0.5 cost-to-charge ratio. Weighted, nationally representative estimates 
of costs per admission (in 2013 US dollars), length of stay (LOS), and case fatality 
rates (CFRs) were descriptively assessed for each year. Results: Total numbers 
of infant pertussis hospitalizations in the US followed a cyclic pattern, starting at 
2,282 in 2000 and peaking at 5,343 in 2005, then declining to 1,614 in 2007 before 
another peak of 3,220 in 2010. Mean [SD] LOS for these hospitalizations fluctuated 
minimally year-to-year, but an overall (albeit modest) increase was observed: from 
3.3 [7.3] days in 2000 to 3.9 [9.5] days in 2010. Mean [SD] cost per admission increased 
at a greater rate than LOS, from $12,377 [$23,985] in 2000 to $16,339 [$37,224] in 2010. 
Both LOS and costs were more than double those observed for non-pertussis hospi-
talizations. CFRs were relatively stable during the period, fluctuating between ~1.5% 
and 3%, although a peak of 4.4% occurred in 2005 coinciding with the incidence 
peak. ConClusions: Infant pertussis hospitalizations typically exceed 3 days and 
are associated with high costs compared with hospitalizations for other causes. 
Observed CFRs were consistent with the ~2% fatality rate previously derived from 
CDC surveillance. These data may help inform economic and cost-effectiveness 
evaluations of future pertussis vaccination programs.
PIN40
cost oF erythroPoIetIN use IN the early access Program oF 
telaPrevIr For the treatmeNt oF metavIr F3-F4 PatIeNts wIth 
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objeCtives: To estimate the direct medical costs associated with the use of eryth-
ropoietin (EPO) in the treatment of anemia in patients with advanced fibrosis and 
cirrhosis (METAVIR F3-F4) receiving telaprevir in association with peg-interferon and 
ribavirin (TVR+PR) in the early access program in Brazil. Methods: Anemia events 
and EPO use during TVR therapy were gathered from published results of 97 patients 
in the early access program (EAP) of TVR in Brazil. Anemia treatment was assumed 
to be one vial of erythropoietin (EPO) 40.000U per week. Medication unit costs were 
gathered from a public (SUS) and private payer perspective in Brazil. Sensitivity 
analysis was carried out for anemia treatment duration and patients with EPO 
use. A sub-analysis was performed to estimate the cost of anemia treatment with 
boceprevir (BOC+PR) based on data from the phase 3 clinical trials. Results: The 
cost of EPO during TVR+PR treatment in the EAP /anemic patient was R$ 10.190,04 
from a private payer perspective compared to R$ 3.545,06 from a SUS perspective. 
The average cost of EPO was R$ 4.727,34 /patient from a private payer perspec-
tive and R$ 1.644,87 /patient from the SUS perspective. Considering the sensitivity 
analysis, the total cost of EPO treatment ranged between R$ 382.126,50-R$ 601.212,36 
from a private payer perspective compared to R$ 132.960,00-R$ 209.190,40 from a 
SUS perspective for all patients. Considering EPO use for BOC+PRr, the average ane-
mia treatment cost was R$ 7.851,34 /patient from a private payer perspective and 
R$ 2.731,86 /patient from a SUS perspective. ConClusions: In a real life setting, 
TVR+PR was associated with EPO use although few patients discontinued treatment. 
Compared to EPO use in clinical trials, TVR+PR was associated with less EPO costs 
than BOC+PR in a real life setting such as the Brazilian EAP.
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objeCtives: The objective was to estimate, in a real-life setting, the health care 
resource utilization, more specifically resource utilization for management of the 
most common adverse events (AE) associated with current treatment of hepatitis 
C virus (HCV) infection. Methods: A retrospective study of the Quebec provin-
cial drug reimbursement program (RAMQ) was conducted using a random sample 
of patients who filed at least one script at the pharmacy for an HCV medication 
(pegylated interferon and ribavirin (peg-Riba) +/- boceprevir or telaprevir) from 
2007 to 2013. Data on medical (excluding nurse visits) and pharmaceutical services 
were extracted from the RAMQ database. We report health care resources used 
during HCV treatment including outpatient physician’s visits and procedures, emer-
gency visits, hospitalization days and costs associated with adverse events, which 
included medical services and medications. Results: A total of 962 patients who 
used at least one HCV medication were included in the study (mean age: 47.9 years 
(SD= 10.7), 61.5% males). The proportion of patients who used Peg-Riba only, Peg-
Riba + boceprevir and Peg-Riba + telaprevir was 90.5%, 8.2% and 3.4% and treatment 
duration was 31.5 weeks, 30.4 weeks and 21.6 weeks respectively. During HCV treat-
ment, the average number of health care resources used per patient was 13.2 physi-
cian’s visits and procedures, 0.8 hospitalization day and 0.8 emergency visit. While 
receiving HCV treatment, 20.8% of patients required erythropoietin, 33.3% received 
rash treatments and 48.8% were treated for depression. Estimated costs associated 
with management of these three AE were CDN$11,199, CDN$85 and CDN$282 per 
patient respectively, for a total of CDN$2,399,258 for this cohort. ConClusions: 
